Related Experiment Videos
Targeted radionuclide therapy for neuroendocrine tumours
1Nuclear Medicine, Southampton University Hospitals NHS Trust, Tremona Road, Southampton SO16 6YD, UK. vjlweington@hotmail.com
Endocrine-Related Cancer
|January 10, 2004
Summary
Targeted radiotherapy offers an effective systemic treatment for neuroendocrine tumors, especially for inoperable or widespread disease. This approach shows low toxicity and requires specific imaging and patient function criteria for success.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiotherapy
Background:
- Neuroendocrine tumors (NETs) present complex management challenges, particularly in advanced stages.
- Targeted radiotherapy has emerged as a promising systemic treatment modality for NETs.
Purpose of the Study:
- To review the current evidence and clinical experience of targeted radiotherapy in managing neuroendocrine tumors.
- To discuss the established (131)I metaiodobenzylguanidine therapy and emerging radiolabeled peptide therapies.
Main Methods:
- Review of clinical experience and published data on targeted radiotherapy for neuroendocrine tumors.
- Focus on therapies like (131)I metaiodobenzylguanidine, (90)Y DOTATOC, and (90)Y lanreotide.
- Assessment of treatment prerequisites, including diagnostic imaging and patient's physiological status.
Main Results:
- Targeted radiotherapy is effective for inoperable or multi-site neuroendocrine tumors.
- Treatment toxicity is generally low, primarily reversible myelosuppression and potential nephrotoxicity.
- Successful treatment relies on high tumor uptake on imaging and stable patient function.
Conclusions:
- Targeted radiotherapy, including (131)I MIBG and radiolabeled peptides, is a valuable systemic option for neuroendocrine tumors.
- Careful patient selection based on imaging and function is crucial for optimal outcomes.
- Further research is warranted to explore future directions in this field.